GO
Loading...

Boston Scientific Corp

More

  • Boston Scientific to Slash 2,300 Jobs Wednesday, 17 Oct 2007 | 5:26 PM ET

    Boston Scientific said on Wednesday it would cut about 2,300 jobs as part of its effort to reduce operating expenses.

  • JNJ, Genentech: What's Ailing Them (And Their Stock) Tuesday, 16 Oct 2007 | 11:44 AM ET

    If you saw the headline, you would've thought that Johnson and Johnson might help power the Dow today. The hybrid pharmaceutical, medical device and consumer healthcare products company handily beat the Street and raised its guidance for the year.

  • Boston Scientific Seen Cutting Thousands of Jobs Tuesday, 16 Oct 2007 | 8:50 AM ET

    Medical device maker Boston Scientific is preparing to slash thousands of jobs to counter slumping sales, according to a media report Tuesday.

  • Medtronic: The Cents of Making Stents Thursday, 11 Oct 2007 | 10:42 AM ET

    Late yesterday an FDA panel of outside experts unanimously recommended the agency approve Medtronic's drug-coated stent called, "Endeavor". Unlike drugs, there is no telegraphed date for an agency decision, but analysts think the FDA will approve the device by the end of the year or early next year.

  • Your Health, Your Trade Wednesday, 10 Oct 2007 | 11:01 PM ET

    BREAKING: Reuters reports FDA panel backs drug-coated stents made by Medtronic (MDT).

  • FDA Warns on Boston Scientific Aortic Stent Trial Monday, 10 Sep 2007 | 6:40 AM ET

    U.S. health regulators charged Boston Scientific with inadequate record-keeping and reporting following the deaths of five patients implanted with an experimental device to treat a dangerous ballooning of the body's main artery.

  • Medtronic to Slash Jobs Amid Slowdown in Key Market Thursday, 6 Sep 2007 | 11:38 AM ET

    Medical device maker Medtronic, feeling the pinch of a slowdown in one of its key markets, will eliminate about 900 jobs through early retirement packages, voluntary and involuntary separations, the company said in a filing.

  • Heart Attack Victims Do Worse on Drug Stents: Study Tuesday, 4 Sep 2007 | 12:32 PM ET

    Patients given drug-coated stents after an acute heart attack are nearly five times more likely to die six months to two years later than those with bare metal forms of the arterial scaffolding, research showed on Tuesday.

  • Court Clears Way for J&J to Sue Over Failed Guidant Deal Thursday, 30 Aug 2007 | 12:46 PM ET

    A U.S. court dismissed some claims in a lawsuit filed by Johnson & Johnson over its failed bid for Guidant.

  • It's Time for the Lightning Round! Wednesday, 8 Aug 2007 | 8:21 PM ET

    Dynegy, NYMEX, RealNetworks and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • It's Time for the Lightning Round! Monday, 6 Aug 2007 | 10:35 AM ET

    Cramer makes the call on Boston Scientific, Spartan Motor, Frontline, UnitedHealth and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Stocks ended another volatile week with a sharp selloff on Friday amid worries about credit markets and a weakening economy. "Bears have control over the tape in the short term," said Alec Young of  Standard & Poor's. "Investors are repricing risk and taking the stock market down a peg or two."

  • Boston Scientific Misses View as Stent Sales Slide Friday, 20 Jul 2007 | 10:30 AM ET
    Boston Scientific Corp.

    Boston Scientific posted a lower-than-expected quarterly profit Friday as sales of its flagship drug-eluting heart stents fell by 32%.

  • Sudden Death Tuesday, 10 Jul 2007 | 10:10 AM ET

    Boston Scientific, Align and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • A federal judge has ruled that some product-liability claims against Boston Scientific over implantable heart defibrillators can proceed, rejecting the medical device maker's motions to dismiss them.

  • A federal judge has ruled that some product liability claims against Boston Scientific over heart defibrillators can proceed, rejecting the medical device company's motions to dismiss them.

  • Medtronic Profit Up 10% as ICD Sales Improve Tuesday, 22 May 2007 | 7:42 PM ET

    Medtronic reported a forecast-beating 10% rise in quarterly earnings on Tuesday on strongsales of its vascular, neurology and diabetes products and improving demand for its heart rhythm devices.

  • Market Misjudges Medical Stock Friday, 11 May 2007 | 6:54 PM ET

    Regulation approval in China recently hurt this company, but Cramer says there's reason to believe the business is on the MEND.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Two studies and an editorial in the journal of the American Medical Association are raising even more questions about the safety of drug-coated stents and could further hurt already-declining sales.

  • Johnson & Johnson Says Will Meet 2007 Forecast Monday, 7 May 2007 | 10:06 AM ET

    Johnson & Johnson on Monday said it will meet a prior 2007 earnings forecast despite the failure of a highly-anticipated heart device in a key study.